PDF Part VI: Summary of the Risk Management Plan - Lægemiddelstyrelsen

List of important risks and missing information Important identified risks  Use in pregnancy  Excess intake of drug Overdose  Use in patients with kidney dysfunction Use in

List of important risks and missing information Important Identified Risks • Hyperkalemia Important Potential Risks • Venous Thromboembolism • Bone fracture/Decrease in bone

Risk Management Plan Page 12/13 II.A List of important risks and missing information Important risks of Icatibant AdAlvo 30 mg/3 ml injektionsvæske, opløsning are risks that need

Risks associated with the medicine and activities to minimise or further characterise the risks Important risks of Lamotrigine 5/25/100 mg chewable/dispersible tablets, together with

Caspofungin RMP v 2.2 TEVA CONFIDENTIAL Page 15 of 25 II.A List of Important Risks and Missing Information Important risks of Caspofungin are risks that need special risk management

List of important risks and missing information Important identified risks  Injection site reactions Important potential risks  Deterioration of cardiac function under ischaemic

Risk Management Plan Page 12/15 II.A List of important risks and missing information Important risks of Icatibant STADA 30 mg/3 ml injektionsvæske, opløsning are risks that need

Risk Management Plan Syri Pharma Limited Midazolam 5mg/ml Oral Solution Version 0.3 Page 42 of 46 List of important risks and missing information Important identified risks 